Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Radiol Oncol ; 53(4): 388-396, 2019 10 25.
Article in English | MEDLINE | ID: mdl-31652121

ABSTRACT

Background Childhood and adult-onset craniopharyngioma is a rare embryogenic tumor of the sellar, suprasellar, and parasellar region. Survival rates are high; however, tumor location and treatment sequalae including endocrine deficits, visual impairment, metabolic complications, cognitive and psychosocial deficits can significantly impair patient's quality of life. There is considerable controversy regarding the optimal management of craniopharyngiomas. Subtotal resection of the tumor followed by targeted irradiation to avoid further hypothalamic damage is currently indicated. Novel insights in the tumor's molecular pathology present the possibility for targeted therapy possibly decreasing the rate and severity of treatment-associated morbidity. Conclusions Craniopharyngioma should be seen as a chronic disease. To achieve optimal outcomes a multidisciplinary team of specialized neurosurgeons, neuro-radiologists, neuro-oncologists, pathologists and endocrinologists should be involved in the diagnosis, planning of the surgery, irradiation and long-term follow-up.


Subject(s)
Craniopharyngioma/diagnostic imaging , Hypothalamic Diseases/physiopathology , Hypothalamus/diagnostic imaging , Magnetic Resonance Imaging , Obesity/physiopathology , Pituitary Neoplasms/diagnostic imaging , Tomography, X-Ray Computed , Adult , Age of Onset , Child , Craniopharyngioma/complications , Craniopharyngioma/pathology , Craniopharyngioma/radiotherapy , Disease Progression , Humans , Hypothalamic Diseases/therapy , Hypothalamus/physiopathology , Neoplasm Grading , Obesity/therapy , Pituitary Neoplasms/complications , Pituitary Neoplasms/pathology , Pituitary Neoplasms/radiotherapy , Prognosis , Quality of Life , Radiosurgery , Survival Rate
2.
Expert Rev Neurother ; 18(10): 793-806, 2018 10.
Article in English | MEDLINE | ID: mdl-30257123

ABSTRACT

INTRODUCTION: Childhood-onset craniopharyngiomas are rare embryonic tumors of low-grade histological malignancy. Severe obesity, physical fatigue, and psychosocial deficits due to hypothalamic tumor involvement have negative impact on quality of life. Initial pretreatment involvement of hypothalamic structures and/or treatment-related lesions result in sequelae clinically associated with impaired social and physical functionality and severe neuroendocrine deficiencies. Overall and progression-free survival rates are not associated with the degree of surgical resection. However, reduced overall survival rates were observed in patients with primary hypothalamic tumor involvement. Areas covered: This review discusses new perspectives on diagnostics, treatment, and follow-up of patients with childhood-onset craniopharyngioma, which were mostly published after 2010 and presented at the 5th International Multidisciplinary Postgraduate Course on Childhood Craniopharyngioma, 19-22 April 2018, at Bad Zwischenahn, Germany. Expert commentary: Percutaneous radio-oncological treatment options are effective in prevention of relapses and tumor progressions. Initial experience with proton beam therapy in childhood-onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment. Recent reports on the molecular pathogenesis of craniopharyngioma open perspectives on the possibility of testing novel treatments targeting pathogenic pathways. As long as effective treatment options for hypothalamic syndrome are not available, hypothalamus-sparing treatment strategies are recommended.


Subject(s)
Craniopharyngioma , Pituitary Neoplasms , Age of Onset , Child , Craniopharyngioma/diagnosis , Craniopharyngioma/pathology , Craniopharyngioma/radiotherapy , Craniopharyngioma/surgery , Disease Progression , Humans , Hypothalamus/pathology , Hypothalamus/surgery , Neoplasm Recurrence, Local/prevention & control , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/pathology , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Quality of Life , Radiotherapy Dosage , Survival Rate , Treatment Outcome
3.
Endocrine ; 51(1): 148-62, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26179178

ABSTRACT

Quality of life of craniopharyngioma patients can be severely impaired by derangement of hypothalamic function. A classification, taking into account preoperative hypothalamic damage, evaluated by magnetic resonance imaging (MRI), and correlating it with postoperative weight change is still missing in the literature. The aim of our study is to identify objective radiological criteria as preoperative prognostic factors for hypothalamic damage. Pre- and post-operative MRI and clinical data of 47 patients, treated at our Institution for craniopharyngioma, were retrospectively analyzed, based on radiological variables, identified as prognostic factor for hypothalamic involvement. Main factors associated with postoperative obesity were hypothalamic hyperintensity in T2-weighted/FLAIR imaging (p < 0.033), mammillary body involvement according to Müller classification (p < 0.020), unidentifiable pituitary stalk (p < 0.001), dislocated chiasm (p < 0.038), either not visible infundibular recess (p < 0.019) or unrecognizable supra-optic recess (p < 0.004), and retrochiasmatic tumor extension (p < 0.019). Accordingly, postoperative hypothalamic syndrome was associated with peritumoral edema in T2-weighted/FLAIR images (p < 0.003), unidentifiable hypothalamus (p < 0.024), hypothalamic compression (p < 0.006), fornix displacement (p < 0.032), and unrecognizable supra-optic recess (p < 0.031). Ultimately, variables identified as predictive factors of postoperative hypothalamic syndrome were the degree of hypothalamic involvement according to the classification described by Sainte-Rose and Puget (p < 0.002; grade 0 vs 2 p < 0.001), Van Gompel (p < 0.002; grade 0 vs 1, p < 0.027; and grade 0 vs 2, p < 0.002), and Muller (p < 0.006; grade 0 vs 1, p < 0.05; and grade 0 vs 2, p < 0.004). The identification of these predictive factors will help to define and score the preoperative hypothalamic involvement in craniopharyngioma patients.


Subject(s)
Craniopharyngioma/diagnosis , Craniopharyngioma/surgery , Hypothalamus/physiopathology , Magnetic Resonance Imaging , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/surgery , Adult , Child , Craniopharyngioma/mortality , Craniopharyngioma/radiotherapy , Female , Humans , Hypothalamus/pathology , Male , Pituitary Neoplasms/mortality , Pituitary Neoplasms/radiotherapy , Predictive Value of Tests , Prognosis , Quality of Life , Retrospective Studies , Treatment Outcome
4.
Int J Radiat Oncol Biol Phys ; 84(4): 990-5, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-22483696

ABSTRACT

PURPOSE: To develop a mathematical model utilizing more readily available measures than stimulation tests that identifies brain tumor survivors with high likelihood of abnormal growth hormone secretion after radiotherapy (RT), to avoid late recognition and a consequent delay in growth hormone replacement therapy. METHODS AND MATERIALS: We analyzed 191 prospectively collected post-RT evaluations of peak growth hormone level (arginine tolerance/levodopa stimulation test), serum insulin-like growth factor 1 (IGF-1), IGF-binding protein 3, height, weight, growth velocity, and body mass index in 106 children and adolescents treated for ependymoma (n=72), low-grade glioma (n=28) or craniopharyngioma (n=6), who had normal growth hormone levels before RT. Normal level in this study was defined as the peak growth hormone response to the stimulation test≥7 ng/mL. RESULTS: Independent predictor variables identified by multivariate logistic regression with high statistical significance (p<0.0001) included IGF-1 z score, weight z score, and hypothalamic dose. The developed predictive model demonstrated a strong discriminatory power with an area under the receiver operating characteristic curve of 0.883. At a potential cutoff point of probability of 0.3 the sensitivity was 80% and specificity 78%. CONCLUSIONS: Without unpleasant and expensive frequent stimulation tests, our model provides a quantitative approach to closely follow the growth hormone secretory capacity of brain tumor survivors. It allows identification of high-risk children for subsequent confirmatory tests and in-depth workup for diagnosis of growth hormone deficiency.


Subject(s)
Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Human Growth Hormone/metabolism , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor I/metabolism , Models, Biological , Adolescent , Arginine , Biomarkers/metabolism , Child , Child, Preschool , Craniopharyngioma/metabolism , Craniopharyngioma/radiotherapy , Ependymoma/metabolism , Ependymoma/radiotherapy , Feasibility Studies , Female , Glioma/metabolism , Glioma/radiotherapy , Human Growth Hormone/deficiency , Humans , Hypothalamus/radiation effects , Infant , Levodopa , Logistic Models , Male , Predictive Value of Tests , Probability , Prospective Studies , ROC Curve , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Conformal , Sensitivity and Specificity
5.
Radiother Oncol ; 82(1): 90-5, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17161483

ABSTRACT

PURPOSE: To describe the technique and results of stereotactically guided conformal radiotherapy (SCRT) in patients with craniopharyngioma after conservative surgery. METHODS AND MATERIALS: Thirty-nine patients with craniopharyngioma aged 3-68 years (median age 18 years) were treated with SCRT between June 1994 and January 2003. All patients were referred for radiotherapy after undergoing one or more surgical procedures. Treatment was delivered in 30-33 daily fractions over 6-6.5 weeks to a total dose of 50 Gy using 6 MV photons. Outcome was assessed prospectively. RESULTS: At a median follow-up of 40 months (range 3-88 months) the 3- and 5-year progression-free survival (PFS) was 97% and 92%, and 3- and 5-year survival 100%. Two patients required further debulking surgery for progressive disease 8 and 41 months after radiotherapy. Twelve patients (30%) had acute clinical deterioration due to cystic enlargement of craniopharyngioma following SCRT and required cyst aspiration. One patient with severe visual impairment prior to radiotherapy had visual deterioration following SCRT. Seven out of 10 patients with a normal pituitary function before SCRT had no endocrine deficits following treatment. CONCLUSION: SCRT as a high-precision technique of localized RT is suitable for the treatment of incompletely excised craniopharyngioma. The local control, toxicity and survival outcomes are comparable to results reported following conventional external beam RT. Longer follow-up is required to assess long-term efficacy and toxicity, particularly in terms of potential reduction in treatment related late toxicity.


Subject(s)
Craniopharyngioma/radiotherapy , Pituitary Neoplasms/radiotherapy , Radiotherapy, Conformal/methods , Adolescent , Adult , Aged , Child , Child, Preschool , Craniopharyngioma/surgery , Disease-Free Survival , Dose Fractionation, Radiation , Female , Follow-Up Studies , Humans , Hypothalamus/radiation effects , Male , Middle Aged , Pituitary Gland/radiation effects , Pituitary Neoplasms/surgery , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Adjuvant , Radiotherapy, Conformal/adverse effects , Treatment Outcome , Vision, Ocular/radiation effects
6.
J Pediatr Endocrinol Metab ; 19 Suppl 1: 367-70, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16700312

ABSTRACT

Craniopharyngiomas remain a therapeutic challenge in terms of treatment-related morbidity. The fact that they are rare, that they are histologically benign, and that anatomically they are located in a challenging area, made them worthy surgical prizes. Whilst surgery has allowed us to meet the challenge of visual salvage, and the advances in hormone replacement therapy are addressing the endocrine challenge, we are becoming increasingly aware that for many children radical resection comes with the cost of devastating effects on quality of life. Increasingly we are recognizing that the next challenge is preservation of hypothalamic function. This consciousness of the morbidity of radical resection has led us, like many pediatric units, to re-examine multimodal treatment strategies. This review examines the Necker experience, aiming to analyze the factors influencing our decision making for treatment.


Subject(s)
Craniopharyngioma/therapy , Pituitary Neoplasms/therapy , Combined Modality Therapy , Craniopharyngioma/radiotherapy , Craniopharyngioma/surgery , Humans , Hypothalamus/physiopathology , Neurosurgical Procedures , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Quality of Life , Risk Assessment , Treatment Outcome
7.
Childs Nerv Syst ; 21(11): 975-80, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16075216

ABSTRACT

OBJECTS: We longitudinally analysed functional capacity and quality of life (QoL) in 102 patients with a childhood craniopharyngioma during follow-up. METHODS: The Fertigkeitenskala Münster-Heidelberg (FMH) ability scale was used for QoL assessment. Multivariate analysis evaluated FMH scores at various time points, examining hypothalamus involvement (HI), body mass index (BMI), degree of resection, tumour progression, relapse and irradiation. RESULTS AND CONCLUSION: Patients without HI (n=60) self-assessed higher QoL at baseline (p=0.001) and follow-up (p<0.001) than patients with HI (n=42). Only patients without HI evaluated at baseline >12 months after diagnosis showed longitudinal improvement in FMH scores (p=0.040). Rates of incomplete resection and irradiation were higher (p=0.070 and p=0.002 respectively) in patients with HI. In multivariate analysis, only HI, tumour relapse, progression, baseline FMH score, and time between diagnosis and baseline evaluation had independent impact on QoL. HI, tumour progression, and relapse had long-term QoL affects-most notably, severe obesity.


Subject(s)
Craniopharyngioma/psychology , Hypophysectomy/psychology , Pituitary Neoplasms/psychology , Quality of Life/psychology , Survivors/psychology , Activities of Daily Living/classification , Activities of Daily Living/psychology , Adolescent , Adult , Body Mass Index , Child , Child, Preschool , Combined Modality Therapy , Craniopharyngioma/radiotherapy , Craniopharyngioma/surgery , Disease Progression , Female , Follow-Up Studies , Humans , Hypothalamus/pathology , Infant , Longitudinal Studies , Male , Neoplasm Invasiveness , Neoplasm Recurrence, Local/psychology , Obesity/psychology , Pituitary Irradiation , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Postoperative Complications/psychology , Psychometrics/statistics & numerical data , Radiotherapy, Adjuvant , Reproducibility of Results , Self-Assessment , Sickness Impact Profile
8.
Klin Padiatr ; 216(6): 343-8, 2004.
Article in English | MEDLINE | ID: mdl-15565549

ABSTRACT

The overall survival rate of patients with craniopharyngioma, an embryogenic malformation, is high (0.92 +/- 0.03). However, there is considerable morbidity and impaired quality of life, even when the tumor can be completely resected. Aim of our study was to analyze risk factors for severe obesity (body mass index [BMI] > or = 7 SD) and the prognosis of severely obese survivors of childhood craniopharyngioma recruited in our cross-sectional study on 183 patients (HIT-ENDO) and in the prospective study KRANIOPHARYNGEOM 2000. Severe obesity (BMI > or = 7 SD) was present in 16 % of patients and associated with higher tumor volume (p < 0.05), more frequent neurosurgical interventions (p < 0.05) and a higher rate of hypothalamic involvement (p < 0.001). Self-assessed functional capacity (FMH) was lower (p < 0.001) in severely obese survivors (FMH: median 33, range: 4-64) when compared with normal weight patients (FMH: 50; 1-95). Overall survival (20 years) was lower (p = 0.034) in patients with severe obesity in comparison to patients with moderate obesity and normal weight. Cardiovascular morbidity and mortality was high in severely obese patients. Between 10/01 and 03/04 fifty-seven patients (27 female/30 male) were recruited in KRANIOPHARYNGEOM 2000 (www.kraniopharyngeom.com). The impact of tumor localization (3.2 % intrasellar, 22.6 % suprasellar, 74.2 % combined intra/suprasellar; 51.6 % hypothalamic involvement) and treatment (26 complete resections, 22 partial resections followed by irradiation in one case; primary irradiation after biopsy in one case) on quality of life, functional capacity and prognosis will be evaluated longitudinally and prospectively.


Subject(s)
Craniopharyngioma , Obesity/etiology , Pituitary Neoplasms , Adolescent , Adult , Body Mass Index , Child , Child, Preschool , Combined Modality Therapy , Craniopharyngioma/complications , Craniopharyngioma/mortality , Craniopharyngioma/radiotherapy , Craniopharyngioma/surgery , Cross-Sectional Studies , Data Interpretation, Statistical , Female , Follow-Up Studies , Humans , Hypothalamus , Infant , Infant, Newborn , Male , Multicenter Studies as Topic , Pituitary Neoplasms/complications , Pituitary Neoplasms/mortality , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Prognosis , Prospective Studies , Quality of Life , Risk Factors , Survival Analysis , Time Factors
9.
J Clin Endocrinol Metab ; 88(2): 611-6, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12574189

ABSTRACT

Hypothalamic obesity, a syndrome of intractable weight gain due to hypothalamic damage, is an uncommon but devastating complication for children surviving brain tumors. We undertook a retrospective evaluation of the body mass index (BMI) curves for the St. Jude Children's Research Hospital brain tumor population diagnosed between 1965 and 1995 after completion of therapy to determine risk factors for the development of obesity. Inclusion criteria were: diagnosis less than 14 yr of age, no spinal cord involvement, ambulatory, no supraphysiologic hydrocortisone therapy (>12 mg/m(2) x d), treatment and follow-up at St. Jude Children's Research Hospital, and disease-free survival greater than 5 yr (n = 148). Risk factors examined were age at diagnosis, tumor location, histology, extent of surgery, hydrocephalus requiring ventriculoperitoneal shunting, initial high-dose glucocorticoids, cranial radiation therapy, radiation dosimetry to the hypothalamus, intrathecal chemotherapy, and presence of endocrinopathy. Analyses were performed both between groups within a risk factor and against BMI changes for age in normal children older than 5.5 yr (the age of adiposity rebound). Risk factors were: age at diagnosis (P = 0.04), radiation dosimetry to the hypothalamus (51-72 Gy, P = 0.002 even after hypothalamic and thalamic tumor exclusion), and presence of any endocrinopathy (P = 0.03). In addition, risk factors when compared with BMI slope for the general American pediatric population included: tumor location (hypothalamic, P = 0.001), tumor histology (craniopharyngioma, P = 0.009; pilocytic astrocytoma, P = 0.043; medulloblastoma, P = 0.039); and extent of surgery (biopsy, P = 0.03; subtotal resection, P = 0.018). These results verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors. In particular, hypothalamic radiation doses of more than 51 Gy are permissive. These results reiterate the importance of the hypothalamus in energy balance, provide risk assessment criteria for preventative measures before the development of obesity in at-risk patients, and suggest therapeutic strategies to reduce the future development of obesity.


Subject(s)
Brain Neoplasms/epidemiology , Craniopharyngioma/epidemiology , Obesity/epidemiology , Astrocytoma/drug therapy , Astrocytoma/epidemiology , Astrocytoma/radiotherapy , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/epidemiology , Cerebellar Neoplasms/radiotherapy , Child , Child, Preschool , Craniopharyngioma/drug therapy , Craniopharyngioma/radiotherapy , Disease-Free Survival , Humans , Hypothalamus/physiology , Medulloblastoma/drug therapy , Medulloblastoma/epidemiology , Medulloblastoma/radiotherapy , Retrospective Studies , Risk Factors
10.
Acta Neurochir (Wien) ; 140(5): 447-54, 1998.
Article in English | MEDLINE | ID: mdl-9728244

ABSTRACT

Although histologically benign, craniopharyngioma can regrow either from macroscopic remnants of the tumour left behind at operation, or even after an apparently gross total removal. Recurrence rates vary significantly in the literature, depending on the efficacy of surgical treatment and also on the growth potential of the tumour itself. The main factor influencing tumour regrowth is obviously the extent of surgical resection, as total removal carries a much lesser risk of recurrence compared to subtotal or partial resections (although in such cases radiation therapy can lower this risk significantly). Other factors involved are the duration of follow-up and patient's age at operation, as children tend to relapse more frequently than adults. Even in the "microsurgery" era, characterized by high percentages of total resections, recurrences remain high and continue to represent a major problem of craniopharyngioma treatment. Twenty-seven children and adolescents were operated on for craniopharyngioma at the Department of Neurosurgery, Section of Pediatric Neurosurgery, Catholic University Medical School, Rome between June 1985 and June 1997. Total tumour resection was achieved in 18 cases, subtotal in 7 and partial in 2 instances. One patient died post-operatively. Post-operative neuroradiological investigations confirmed the operative findings, although 3 children with an apparently gross total removal showed a residual non-enhancing calcium fleck adherent to the hypothalamus (which remained stable at the following examinations). Three of the 9 patients with less than total removal underwent post-operative radiation therapy. Out of the 26 surviving patients 6 presented a recurrence of their craniopharyngioma, 2 after an apparently gross total removal and 4 after a subtotal or partial resection (one of them had received radiation therapy). The diagnosis was merely neuroradiological in 5 cases, as only one child presented a clinical picture suggestive of tumour regrowth. Surgery was the first therapeutic option in all the cases. Total tumour resection was accomplished in 3 cases, subtotal in 2 and partial in the last one. One child died post-operatively. Four of the 5 survivors received radiation therapy. All the patients are presently alive and stable (mean follow-up: 5.6 yrs). The authors conclude that surgery should be the first therapeutic option in case of recurrent craniopharyngioma and that radiation therapy should also be considered but only as adjuvant therapy.


Subject(s)
Craniopharyngioma/surgery , Neoplasm Recurrence, Local/prevention & control , Adolescent , Child , Child, Preschool , Combined Modality Therapy , Craniopharyngioma/diagnosis , Craniopharyngioma/radiotherapy , Female , Follow-Up Studies , Humans , Infant , Magnetic Resonance Imaging , Male , Neoplasm Recurrence, Local/radiotherapy , Neoplasm Recurrence, Local/surgery , Neoplasm, Residual , Patient Selection , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Postoperative Complications , Radiotherapy, Adjuvant , Reoperation/methods , Time Factors , Treatment Outcome
11.
J Neurosurg ; 77(4): 545-50, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1527612

ABSTRACT

Visual function, endocrinological status, and radiological outcome are reported in 31 patients harboring a cystic craniopharyngioma, who underwent 35 intracavitary brachytherapy procedures with yttrium-90. In 26 of these patients intracavitary brachytherapy was the primary treatment. The follow-up period ranged from 2 to 80 months (41 +/- 22 months, mean +/- standard deviation). Five patients died from tumor-related causes. Endocrine recovery was modest. Prior to brachytherapy, visual acuity was diminished in 38 eyes and field defects were present in 46. Funduscopy before treatment revealed optic atrophy in 47% of the eyes. Visual acuity improved in 29% of the eyes studied, remained stable in 13%, and deteriorated in 58%. Visual field defects improved in 28% of the eyes studied, remained stable in 20%, and deteriorated in 52%. The possible causes for deterioration in visual function are discussed. Complete resolution of 10 cysts was noted. In 12 patients the size of the cyst decreased; however, in three of these patients new cyst formation took place. The cyst size stabilized in six cases and increased in three. Although there is still a substantial degree of visual function deterioration following intracavitary brachytherapy, morbidity is otherwise low, making this treatment modality a reasonable alternative to craniotomy.


Subject(s)
Brachytherapy , Craniopharyngioma/radiotherapy , Pituitary Neoplasms/radiotherapy , Yttrium Radioisotopes/administration & dosage , Adolescent , Adult , Brachytherapy/adverse effects , Child , Child, Preschool , Craniopharyngioma/complications , Craniopharyngioma/diagnostic imaging , Craniopharyngioma/mortality , Endocrine System Diseases/etiology , Eye Diseases/etiology , Eye Diseases/physiopathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pituitary Neoplasms/complications , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/mortality , Quality of Life , Survival Rate , Tomography, X-Ray Computed , Treatment Outcome , Visual Acuity/physiology , Visual Fields/physiology
13.
Cancer ; 35(1): 111-20, 1975 Jan.
Article in English | MEDLINE | ID: mdl-162849

ABSTRACT

Three types of tumor (supratentorial astrocytoma, medulloblastoma, and craniopharyngioma), each requiring a fundamentally different therapeutic approach, will be used to illustrate the principles and practice of combined treatment in this field. The role of radiotherapy and ways of enhancing the effect of irradiation will be considered. Attention will be given to adjuvant chemotherapy and to multiple drug regimes. Reference will be made to an early effort at immunotherapy following the initial reduction of tumor cell load by surgery and irradiation.


Subject(s)
Astrocytoma/therapy , Brain Neoplasms/therapy , Craniopharyngioma/therapy , Medulloblastoma/therapy , Antigens, Neoplasm , Antineoplastic Agents/therapeutic use , Astrocytoma/radiotherapy , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Carmustine/therapeutic use , Child , Craniopharyngioma/radiotherapy , Craniopharyngioma/surgery , Glioblastoma/radiotherapy , Glioma/radiotherapy , Humans , Hyperbaric Oxygenation , Hypothermia, Induced , Immunotherapy , Medulloblastoma/drug therapy , Medulloblastoma/radiotherapy , Neutrons , Nitrosourea Compounds/therapeutic use , Radiation-Sensitizing Agents , Radiotherapy Dosage , Radiotherapy, High-Energy
SELECTION OF CITATIONS
SEARCH DETAIL